Barclays PLC raised its position in shares of Bank7 Corp. (NASDAQ:BSVN – Free Report) by 25.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,287 shares of the company’s stock after buying an additional 3,334 shares during the quarter. Barclays PLC’s holdings in Bank7 were worth $760,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Inspire Investing LLC purchased a new position in shares of Bank7 in the fourth quarter valued at $893,000. Geode Capital Management LLC lifted its position in Bank7 by 1.7% during the third quarter. Geode Capital Management LLC now owns 96,321 shares of the company’s stock valued at $3,610,000 after purchasing an additional 1,633 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Bank7 by 674.6% in the 4th quarter. JPMorgan Chase & Co. now owns 13,370 shares of the company’s stock worth $624,000 after buying an additional 11,644 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Bank7 by 40.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 20,418 shares of the company’s stock valued at $953,000 after buying an additional 5,871 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its holdings in shares of Bank7 by 86.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 34,770 shares of the company’s stock valued at $1,622,000 after acquiring an additional 16,099 shares during the last quarter. Institutional investors own 23.48% of the company’s stock.
Bank7 Price Performance
Shares of NASDAQ:BSVN opened at $36.92 on Wednesday. The business has a 50 day simple moving average of $37.74 and a two-hundred day simple moving average of $42.15. Bank7 Corp. has a 1 year low of $27.36 and a 1 year high of $50.26. The firm has a market capitalization of $348.82 million, a PE ratio of 7.63 and a beta of 1.07.
Insiders Place Their Bets
In other news, insider Douglas A. Haines acquired 1,433 shares of Bank7 stock in a transaction on Wednesday, March 5th. The shares were bought at an average cost of $39.91 per share, for a total transaction of $57,191.03. Following the acquisition, the insider now directly owns 18,542 shares of the company’s stock, valued at $740,011.22. This trade represents a 8.38 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Henry Litchfield sold 5,000 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $41.54, for a total transaction of $207,700.00. Following the transaction, the vice president now owns 13,375 shares in the company, valued at approximately $555,597.50. The trade was a 27.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 25.81% of the company’s stock.
Analyst Ratings Changes
Several brokerages have weighed in on BSVN. Piper Sandler boosted their price objective on Bank7 from $53.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Keefe, Bruyette & Woods decreased their price target on Bank7 from $50.00 to $47.00 and set an “outperform” rating on the stock in a report on Friday, April 11th.
Get Our Latest Analysis on BSVN
Bank7 Profile
Bank7 Corp. operates as a bank holding company for Bank7 that provides banking and financial services to individual and corporate customers. It offers commercial deposit, commercial checking, money market, and other deposit accounts; and retail deposit services, such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access.
See Also
- Five stocks we like better than Bank7
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Mid-Cap Medical Stocks Outperforming the Market
- Profitably Trade Stocks at 52-Week Highs
- The Top-Ranked Insider Buys From April by Market Cap
- 5 Top Rated Dividend Stocks to Consider
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Want to see what other hedge funds are holding BSVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bank7 Corp. (NASDAQ:BSVN – Free Report).
Receive News & Ratings for Bank7 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bank7 and related companies with MarketBeat.com's FREE daily email newsletter.